Salman Punekar, Assistant Professor of Medicine at NYU Langone Health, shared on LinkedIn:
“Treatment for RAS-mutated cancers has come so far it’s hard to believe. Today we published groundbreaking results of a trial of Daraxonrasib in lung cancer in the NEJM.
Working with such amazing colleagues at the most top notch institutions around the country and at RevMed on this phase 1-2 trial for Daraxonrasib in lung cancer is definitely one of my proudest moments in the past few years.
Tons of gratitude for my mentors, team, collaborators, and of course the patients who enrolled. You all made this happen.
Let’s keep chipping away!”
Title: Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer
Authors: Kathryn C. Arbour, Salman Punekar, Jia Luo, Melissa Johnson, Alexander Spira, Benjamin Herzberg, Alexander Starodub, David Sommerhalder, Joel Randolph Hecht, Ignacio Garrido-Laguna, Minal Barve, Sai-Hong Ignatius Ou, Sumit Kar, Lei Bao, Lin Tao, Rashmi Vora, Aparna Hegde, Andreas Saltos, Nilofer S. Azad, David S. Hong.
You can also read: Tumor Immune Changes Predict Immunotherapy Response – Lung Cancer Europe
